Ray Blanco

Increasingly, the great new medical technologies aren’t coming from the pharmaceutical behemoths, but from scrappy little biotech upstarts. In few instances is this truer than in the field of cancer immunotherapy.

Immunotherapy is defined as a “treatment designed to produce immunity to disease or enhance the resistance of the immune system to an active disease process, as cancer.” Simply put, cancer immunotherapy activates the body’s powerful and complex immune system so that it can do its job better.

Immune system-based therapies are becoming a proven route to improving cancer treatment. There are multiple immunotherapy innovators, several of which have performed well in our Technology Profits Confidential portfolio due to their deep and diverse developmental pipelines.

Some immune-based therapies work, for example, by training the immune system to identify and attack cancer cells. Functionally, therefore, they are vaccines.

Others use antibodies to achieve similar results. Antibodies are an important part of our natural biological defenses. They are used by the immune system to identify infectious microbes and mutant cancer cells. Once these foreign objects are flagged by antibodies, other immune system components, such as white blood cells, move in for the kill.

ADC (antibody-drug conjugation) technology, for example, works by combining an immune system component — antibodies — with a toxic payload.

ADC technology uses engineered antibodies to target molecular markers that are overexpressed on cancer cells, yet absent or uncommon on healthy ones. The attached toxin is then released to kill the cell.

Another kind of ADC technology doesn’t link antibodies directly to cancer cells, but instead, attach an antigen to an antibody that is targeted to attach to antigen-presenting cells (APCs) — specifically, dendritic cells. Once attached to a dendritic cell, it presents an antigen that’s frequently present in a wide variety of cancer types, including sarcoma, myeloma, melanoma and cancer of the bladder, breast, ovaries and lungs.

Many antibody-based cancer immunotherapy companies imitate this natural defense mechanism by creating custom antibodies to home in on molecular targets present on cancer cells. Once an immune system cell, such as a T-cell, comes into contact with an attached antibody, it attacks the tagged cancer cell.

Then there’s technology that uses compounds that aren’t antibodies, but protein that stimulates the immune system by proliferating and mobilizing bone marrow stem cells and immune cells.

When choosing different companies that specialize in this kind of technology, many factors come into play. But when picking companies undergoing trials, it’s better to go with fully human antibody therapeutics over “humanized” mouse (or any other animal) antibody.

When it’s fully human, it should be better tolerated by human patients. Humans can have an immune reaction to nonhuman antibodies, paradoxically producing their own antibodies to the therapeutic antibody. This causes the patient’s immune system to destroy the therapeutic antibodies.

This can reduce the effectiveness of an antibody therapy and require more frequent dosing. And because antibody drugs are large proteins that must be administered through injection, the frequency of dosing is important to patients.

Takeaway: keep these kinds of immunotherapy approaches in mind when looking for biotech companies with high growth potential.

Ad lucrum per scientia (toward wealth through science),

Ray Blanco

Ray Blanco

In 8th grade Ray Blanco was in his basement learning how to build what's called a "Wilson Cloud Chamber," a supercooled device for detecting particles of ionizing radiation. Now, he is an expert in advanced robotics, avionics, genomics, and biotechnology. Blanco was raised in Miami,FL, after his family fled Cuba in the 1960s. He is co-editor of Technology Profits Confidential and contributes to Breakthrough Technology Alert and Tomorrow in Review.

Recent Articles

Bill Bonner
Confessions of a Newsletter Man

Bill Bonner

Being a financial newsletter writer certainly has a few advantages. Namely, it affords one the opportunity to comment on the financial markets without having to take them seriously. Today, Bill Bonner looks back on what drew him to this business, and the unique and entertaining cast of characters he's met along the way. Read on...

In the Year 2024

James Rickards

Panopticon goggles? Severe market panic in 2018? Gold confiscation by 2020? Jim Rickards' shocking thought-piece in the spirit of A Brave New World or 1984. Click to see how markets, economics, your money, gold, privacy, wealth building and more look a decade from now in the year 2024...

Buy Solar Before 2015

Stephen Petranek

This is the time of year when investors are easily distracted. Oil is down, and it’s creating a drastic mispricing in the solar markets. Science expert Stephen Petranek says one solar company is mispriced by as much as 40%... but it might not last until January.

We May Have Reached “Peak Shale” – Here’s Why That’s Good News!

Jody Chudley

I don't know how low the price of oil will ultimately go in the near future, but I do know that the seeds for an oil price recovery are already being planted by North American shale producers. These companies are dramatically slashing their capital spending plans for 2015, and I believe that the impact on production will surprise the markets…

“Can We Talk?”

Dave Gonigam

Our discussions in these pages tend to freak new readers out. Dave Gonigam and Addison spent a fair amount of time last week discussing the implications of a deflationary environment and Fed policies on your existing portfolio. Dave sums up their conclusion in a neat gift box with a tight bow on it in today's essay.